Cabazitaxel Improves rPFS in Patients with mCRPC
Daniel P. Petrylak, MD, discusses the efficacy results from the CARD trial, which evaluated the radiographic progression-free survival of cabazitaxel combined with either abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.<br />
Daniel P. Petrylak, MD, professor of medicine and urology and co-leader, Cancer Signaling Networks, Yale Cancer Center, discusses the efficacy results from the CARD trial, which evaluated the radiographic progression-free survival (rPFS) of cabazitaxel (Jevtana) combined with either abiraterone acetate (Zytiga) or enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer (mCRPC).
The results showed that the use of cabazitaxel achieved better rPFS than either second-generation antiandrogen. This suggests that patients still have resistance to second-generation hormonal agents but, currently, there is no algorithm for understanding which agent should be administered and when.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
